EXAS
Exact Sciences Corporation · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q1 2026 | 1 | -143 | 11.48K | $1.20M | — | −144 |
| Q4 2025 | 146 | +2 | 107.45M | $10.91B | +5 | −2 |
| Q3 2025 | 23 | +1 | 95.08M | $5.20B | +1 | −1 |
| Q2 2025 | 20 | 0 | 105.61M | $5.61B | — | — |
| Q1 2025 | 17 | -2 | 51.51M | $2.23B | +1 | −3 |
| Q4 2024 | 19 | +2 | 51.81M | $2.91B | +3 | −1 |
| Q3 2024 | 16 | -2 | 41.47M | $2.82B | — | −2 |
| Q2 2024 | 18 | — | 42.26M | $1.79B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 16.50M | — | $697.18M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 14.79M | — | $624.81M | 0.1% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 14.79M | — | $624.81M | 0.1% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 14.79M | — | $624.81M | 0.1% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 14.79M | — | $624.81M | 0.1% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 14.79M | — | $624.81M | 0.1% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 14.79M | — | $624.81M | 0.1% | n/c | 1 | SEC ↗ |
| 8 | Wellington Management ✦ | 14.79M | — | $624.81M | 0.1% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 3.10M | — | $130.68M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passive) | 3.10M | — | $130.68M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Baillie Gifford ✦ | 1.43M | — | $60.27M | 0.0% | n/c | 1 | SEC ↗ |
| 12 | Baillie Gifford ✦ | 1.43M | — | $60.27M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Baillie Gifford ✦ | 1.43M | — | $60.27M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Baillie Gifford ✦ | 1.43M | — | $60.27M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Norges Bank ✦ (passive) | 1.24M | — | $52.48M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 1.19M | — | $50.07M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 1.19M | — | $50.07M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Millennium Management ✦ | 674.86K | — | $28.51M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Glenview Capital ✦ | 629.46K | — | $26.59M | 0.6% | n/c | 1 | SEC ↗ |
| 20 | Renaissance Technologies ✦ | 510.70K | — | $21.58M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | PRIMECAP Management ✦ | 496.30K | — | $20.97M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Citadel Advisors ✦ | 461.34K | — | $19.49M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | Citadel Advisors ✦ | 461.34K | — | $19.49M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | ARK Investment Management ✦ | 344.49K | — | $14.55M | 0.1% | n/c | 1 | SEC ↗ |
| 25 | Soros Fund Management ✦ | 225.00K | — | $9.51M | 0.3% | n/c | 1 | SEC ↗ |
| 26 | Point72 Asset Management ✦ | 195.77K | — | $8.27M | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Fisher Asset Management ✦ | 159.20K | — | $6.73M | 0.0% | n/c | 1 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 153.60K | — | $6.49M | 0.0% | n/c | 1 | SEC ↗ |
| 29 | AQR Capital Management ✦ | 153.60K | — | $6.49M | 0.0% | n/c | 1 | SEC ↗ |
| 30 | AQR Capital Management ✦ | 153.60K | — | $6.49M | 0.0% | n/c | 1 | SEC ↗ |
| 31 | AQR Capital Management ✦ | 153.60K | — | $6.49M | 0.0% | n/c | 1 | SEC ↗ |
| 32 | Gotham Asset Management ✦ | 131.55K | — | $5.56M | 0.1% | n/c | 1 | SEC ↗ |
| 33 | D. E. Shaw & Co. ✦ | 40.25K | — | $1.70M | 0.0% | n/c | 1 | SEC ↗ |
| 34 | D. E. Shaw & Co. ✦ | 40.25K | — | $1.70M | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 9 holders, 64.35K shares, $4.50M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.